Angiogenic Agent Using Immunoisolation Membrane
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing methods for using mesenchymal stem cells (MSCs) in regenerative medicine face challenges such as immune rejection and the need for immunosuppressant agents, which come with side effects, limiting their therapeutic efficacy.
Innovation Solution
An angiogenic agent is developed using an immunoisolation membrane to enclose mesenchymal stem cells, preventing immune rejection while allowing angiogenesis, comprising a porous membrane with specific pore diameters and thickness, and biocompatible polymer blocks to stabilize and deliver nutrients.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If allogeneic mesenchymal stem cells are used for treatment, then the availability and scalability are improved, but immune rejection occurs and eliminates the transplanted cells over time
Solution Approach 1:
An immunoisolation membrane is introduced as an intermediary between the allogeneic mesenchymal stem cells and the host immune system. The membrane allows selective permeation: it permits nutrients, oxygen, and signaling molecules to reach the cells while blocking immune cells and antibodies from attacking them. This resolves the contradiction by maintaining cell viability (improving reliability) while still enabling the use of allogeneic cells (maintaining productivity).
Solution Approach 2:
The immunoisolation membrane functions as a flexible protective shell that encloses the mesenchymal stem cells. This thin film structure provides physical protection against immune rejection while maintaining the necessary exchange of substances through its selective permeability. The membrane's flexibility allows it to conform to the cells and maintain their function, thus preserving cell survival rates while enabling allogeneic cell therapy.
2Reliability
If an immunosuppressant agent is used to prevent rejection, then immune rejection is reduced, but side effects and permanent use burden increase
Solution Approach 1:
The harmful immunosuppressant agents are extracted from the treatment system entirely. Instead of using chemicals to suppress the immune system, the invention uses a physical barrier (the immunoisolation membrane) to prevent immune rejection. This eliminates the side effects associated with immunosuppressants while maintaining the protective function, thus improving reliability without introducing harmful factors.
3Reliability
If a selectively permeable membrane is used to prevent immune reaction, then immune rejection is avoided, but the complexity of the device increases
Solution Approach 1:
The immunoisolation membrane utilizes porous material structure to achieve selective permeability. The porous structure allows small molecules like oxygen and nutrients to pass through while blocking larger immune cells and proteins. This natural filtration capability of porous materials provides the necessary immune protection without requiring complex active control mechanisms, thus maintaining relatively simple device structure while achieving reliable immune reaction evasion.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The angiogenic agent effectively promotes angiogenesis without immune rejection, creating new blood vessels and providing a long-term therapeutic effect.
Implementation Method 1
a selectively permeable membrane that allows the permeation of oxygen, nutrients, and metabolic products and inhibits the permeation of immune cells and antibodies involved in an immune rejection
Implementation Method 2
an immunoisolation membrane that allows the permeation of oxygen, nutrients, and metabolic products and inhibits the permeation of immune cells and antibodies
Data Source
Figure 1
Figure 2
Figure 3
AI summary
An object of the present invention is to provide an angiogenic agent that can sufficiently exhibit an angiogenic effect due to mesenchymal stem cells in a state where the angiogenic agent does not allow permeation of host cells while being protected from immune rejection, and a method for method for manufacturing the same. According to the present invention, an angiogenic agent including a mesenchymal stem cell (A); and an immunoisolation membrane (B) that encloses the mesenchymal stem cell is provided.